Genetic mutations predict patient response to immunotherapy

Results of a new clinical study establish particular genetic defects in tumors as clinical indicators for successful response to a type of immunotherapy called PD-1 blockade. Until recently, PD-1 blockade therapies have only been approved for a select few classes of cancers, such as colon cancer. Because clinical tests for the particular indicator defects identified here are widely available, these results could establish a new...